AMTI - Applied Molecular Transport Inc.

0.263
-0.044   -16.692%

Share volume: 0
Last Updated: 12-26-2023

PREVIOUS CLOSE
CHG
CHG%
$0.31
-0.04
-14.30%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Historical prices Events Documents Notes Dividends
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-5.45%
1 Month
-9.09%
3 Months
11.11%
6 Months
-50.36%
1 Year
-84.92%
2 Year
-98.96%
Key data
Stock price
$0.26
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.21 - $2.09
52 WEEK CHANGE
-$0.84
MARKET CAP 
11.801 M
YIELD 
N/A
SHARES OUTSTANDING 
39.338 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
1.27
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$29,414
AVERAGE 30 VOLUME 
$75,599
Company detail
CEO: Tahir Mahmood
Region: US
Website: appliedmt.com
Employees: 120
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry:
Sector:

Applied Molecular Transport Inc. engages in the design and development of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis.

Recent news